about
Erythema elevatum diutinum.Topical tacrolimus in the treatment of symptomatic oral lichen planus: a series of 13 patients.Amyopathic dermatomyositis: retrospective review of 37 cases.Pityriasis rubra pilaris in children.Efficacy, safety, and cost of Goeckerman therapy compared with biologics in the treatment of moderate to severe psoriasis.Thalidomide for dermatology: a review of clinical uses and adverse effects.Rituximab: applications in dermatology.Changing trends and allergens in the patch test standard series: a mayo clinic 5-year retrospective review, january 1, 2001, through december 31, 2005.Clinical, histopathologic, and immunophenotypic features of lymphomatoid papulosis with CD8 predominance in 14 pediatric patients.Does pancreas transplant in diabetic patients affect the evolution of necrobiosis lipoidica?Wet dressing therapy in conjunction with topical corticosteroids is effective for rapid control of severe pediatric atopic dermatitis: experience with 218 patients over 30 years at Mayo Clinic.Retrospective analysis of tissue plasminogen activator as an adjuvant treatment for calciphylaxis.Pharmacogenetics in dermatology: a patient-centered update.Acute graft-versus-host disease after liver transplantation diagnosed by fluorescent in situ hybridization testing of skin biopsy specimens.Chronic hepatitis C, cryoglobulinemia, and cutaneous necrotizing vasculitis. Clinical, pathologic, and immunopathologic study of twelve patients.Studies on the mechanism of 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea (CCNU)-induced hepatotoxicity. II. Biochemical and morphological characterization of the injury and its prevention by phenobarbital.Beard dermatitis due to para-phenylenediamine use in Arabic men.Dermatologic side effects of thalidomide in patients with multiple myeloma.Experience with the dermatology inpatient hospital service for adults: Mayo Clinic, 2000-2010.Therapeutic dose monitoring of mycophenolate mofetil in dermatologic diseases.Pediatric hospital dermatology: experience with inpatient and consult services at the Mayo Clinic.Oral bexarotene in a therapy-resistant Sézary syndrome patient: observations on Sézary cell compartmentalization.Missed opportunities in residency education: the role of hospital dermatology.Thioguanine nucleotides and thiopurine methyltransferase in immunobullous diseases: optimal levels as adjunctive tools for azathioprine monitoring.Sweet syndrome as a manifestation of azathioprine hypersensitivity.Bexarotene treatment of late-stage mycosis fungoides and Sézary syndrome: development of extracutaneous lymphoma in 6 patients.A morbilliform variant of vancomycin-induced linear IgA bullous dermatosis.Patch test results from the Mayo Clinic Contact Dermatitis Group, 1998-2000.Do antihistone autoantibodies reflect disease activity in linear scleroderma?Sclerotherapy of spider veins using the accurate depth-gauge collagen needle.Tissue distribution and macromolecular interactions of 14[C-ring] melphalan in the rat.Dermatology and early Human Immunodeficiency Virus (HIV)/Acquired Immune Deficiency Syndrome (AIDS) recognition in Faith Alive Clinic Jos, Nigeria: a third year medical student experience.Oral metal contact allergy: a pilot study on the cause of oral squamous cell carcinoma.Immunophenotyping of chimeric cells in localized scleroderma.A comparison of morphologic features, flow cytometry, TCR-Vbeta analysis, and TCR-PCR in qualitative and quantitative assessment of peripheral blood involvement by Sézary syndrome.Cutaneous manifestations in patients with POEMS syndromeStudies on the mechanism of 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea (CCNU)-induced hepatotoxicity. III. Ultrastructural characterization of bile duct injuryDisseminated cutaneous Mycobacterium avium-intracellulare resembling sarcoidosisThe spectrum of cutaneous granulomatous vasculitis: histopathologic report of eight cases with clinical correlationContact Allergen Avoidance Program: a topical skin care product database
P50
Q33944662-BC00C0E8-537C-43AE-8F6E-AE729943F22AQ34470565-99A35AAE-98D8-419F-8513-FE983E658F7DQ34573083-FCB4C1DA-99AE-4E49-8BE0-8772776B1890Q34798152-1FE0FF3C-661A-450D-B414-2E534830659DQ34987655-96AA3B3B-1B3D-466D-839F-B3EA524B0FC9Q36016846-AB3F0D5E-6EF1-48AC-9343-8978F3AB0E06Q36623217-7C481D65-57F8-4F21-969D-A6F57866FAE1Q37061743-C5E419AE-A57B-4B78-BDF5-8824963914EFQ37541089-D889662A-861F-4CA2-9937-F4F9CAB7230AQ37585567-ECAB7AE1-640B-4834-8A61-722C3F9CAE77Q37943044-D33BD5A7-9540-4641-B1D7-E62523A1A6D7Q38074532-783A3C23-AAEA-4DDC-8A86-8257987C8946Q38115822-DB06FE52-E9EE-4D4D-BB91-04ED1338E672Q40468649-67EC731A-B551-451E-B1D8-E9A4D770C9F8Q40993951-AB0A1CE9-8AB4-4533-B07A-4F07CC6DC883Q42208026-B1787DE7-7647-4C33-9E50-E4982A22E8D5Q43581761-73CBE41B-839E-4A0B-B841-2D2168307A47Q44381698-77E38D11-42E6-46C9-B4D7-9E2FEDE4F386Q44524839-19B7F3F8-6018-438C-9A84-DAB86D8A48FFQ44579770-8FD2A66A-3976-4D81-B58F-9BB9A6D0E76DQ44635262-4EFA2D74-5695-422B-9B2D-4F13331EAE11Q45233151-63A6B39F-D49C-45F0-B277-DE48A905D6BCQ45736126-738FECC0-ADE2-4A3A-9AA7-64DD45D4BB8EQ45968242-C745E5D2-9FF7-48F4-B2A3-5B8F5EE72617Q46385708-B45A5A7D-55F5-4D08-837E-7A2EB9B4A4DBQ46521149-1CC9E819-D5C9-46DC-B33E-A4C02A0F16EDQ46535539-4EE97341-4173-479D-9D5E-974C0F307659Q46660517-43734DEA-1E26-4B34-920C-AEAB80640A62Q47311252-0252654B-11F1-4D26-98E7-BB36338EEF6BQ47965732-E236DEF3-A75A-4A76-AB31-FCFAA9A5AAA7Q49040235-07EF9907-5639-4A66-9573-AE875971A2E2Q50606885-40F3B62D-7A7C-4B3F-91DD-CBFA01F0ED2CQ51248564-1CE4D884-B765-407C-B78C-EB0927234F4AQ51777858-FC1FB188-04E8-4CF7-9B7F-7683134228FEQ53627673-E0A2172C-2FCB-4B01-A52A-950B3A172CB0Q60976506-3457B6C9-C2AF-41BE-A09F-3EBF9A8F4FF8Q68986068-32604D58-9308-4C95-AAA8-49C3F37771EAQ72017612-46ACC7DB-D5C0-45CD-800A-ADACF9EC0D22Q72574756-207632A4-AA58-41D9-800B-5948C761FAD2Q73312107-31776F16-473F-4842-BD48-5CE5E1646412
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Rokea A el-Azhary
@ast
Rokea A el-Azhary
@en
Rokea A el-Azhary
@es
Rokea A el-Azhary
@nl
Rokea A el-Azhary
@sl
type
label
Rokea A el-Azhary
@ast
Rokea A el-Azhary
@en
Rokea A el-Azhary
@es
Rokea A el-Azhary
@nl
Rokea A el-Azhary
@sl
altLabel
azhary el azhary, elazhary
@en
prefLabel
Rokea A el-Azhary
@ast
Rokea A el-Azhary
@en
Rokea A el-Azhary
@es
Rokea A el-Azhary
@nl
Rokea A el-Azhary
@sl
P106
P108
P1153
7004140564
P31
P496
0000-0002-1752-0294